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Abstract 
In patients with liver-limited metastatic colorectal cancer, hepatic resection can offer 
a significant survival benefit over systemic therapy alone. Specialist hepatobiliary 
multidisciplinary meetings are currently believed to provide the best forum to discuss 
the management for these patients.  
A retrospective analysis was undertaken of patients diagnosed with liver-limited 
metastatic colorectal cancer over 6 months within a cancer network in the United 
Kingdom. In addition, patients who were diagnosed but not referred to the 
hepatobiliary meeting were discussed within a virtual multi-disciplinary setting. 
Contributors were blinded and proposed management recorded.  
159 newly diagnosed patients with liver-limited metastatic colorectal cancer were 
identified. 68 (43%) were referred at initial diagnosis and 38 (24%) referred following 
systemic treatment. 35 (51%) who were discussed at baseline underwent a 
subsequent hepatectomy or radio frequency ablation, as did 18 (47%) patients 
referred after chemotherapy. Of the remaining 53 (33%) patients not referred, 
imaging was available for 31 (58%). Decisions regarding potential liver-directed 
therapy were discussed within a multi-disciplinary setting. 13 (41.9%) were identified 
as resectable or potentially resectable and 11 (35.5%) may have been suitable for a 
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clinical trial. In reality, none of these 31 patients (100%) underwent surgery or 
ablation.  
Whilst the majority of patients with liver-limited metastatic colorectal cancer were 
referred appropriately, this study demonstrates that a significant number with 
potentially resectable disease are not being discussed at specialist meetings.  A 
review of all diagnosed cases would ensure that an increased number of patients are 
offered hepatic resection or ablation. 
 
 
 
Clinical outcomes for patients with liver-limited metastatic colorectal cancer: 
Arguing the case for specialist multidisciplinary assessment 
 
 Background 
Colorectal cancer (CRC) is the 3rd leading cause of cancer related mortality worldwide. 
Advances in systemic therapy have changed the treatment paradigm of stage IV disease 
and the median overall survival for metastatic CRC is now 26-30 months with 5 year 
survival rates of 11% [1-3]. Yet there is mounting evidence demonstrating improved 
outcomes in a select group of patients with resectable liver-limited metastases. R0 
hepatic resections can lead to 5-year survival rates of 36-58% and 10 year figures can 
reach 17%-26%[4-6]. In CRC, the liver is often the initial site of metastatic spread due to 
direct invasion via the hepatic portal vein. 20% of patients with Stage IV disease present 
with CRC liver metastases (CLM) with a further 50% or more developing subsequent 
metachronous CLM. As several retrospective studies have now demonstrated 
significantly improved survival following hepatic metastasectomies, it is no longer 
justifiable to perform randomised trials comparing surgery with systemic treatment 
alone[5-7].  
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As expected, an R0 resection is required to achieve optimal survival and thus liver 
metastasectomy remains a highly skilled procedure. In the United Kingdom (UK) these 
operations are restricted to specialist hepato-biliary (HPB) units following discussion 
within a specialist HPB oncology multi-disciplinary meeting (MDM).  Each MDM should 
include dedicated HPB surgeons, radiologists and oncologists. A proposed pan-
European consensus suggested that MDM discussions should take place both at 
presentation and prior to subsequent major treatment decisions[8]. Current National 
Institute for Health Care and Excellence (NICE) guidelines state that if a computer 
tomography [9] scan of a patient with CRC shows metastases confined to the liver, a 
specialist HPB MDM should decide whether further imaging is needed to confirm 
whether surgery is possible for the patient (or potentially possible) after further 
treatment [10]. NICE guidance also states that local cancer networks should agree pre-
determined criteria specifying which patients should be referred to the HPB MDM. 
However the definition of what constitutes resectable disease continues to evolve with 
advancing surgical and imaging techniques and therefore should only be determined by 
a specialist team. Historically, metastasectomies were reserved for patients with 
isolated liver lesions. Yet the combination of novel systemic therapies and more 
sophisticated surgical procedures mean resections can now be offered to patients with 
more extensive disease. Therefore many clinicians are now of the opinion that all 
patients with limited CLM should be referred for specialist HPB MDM review to avoid 
inappropriately denying patients surgery. Patients not suitable for hepatic resection, 
but with isolated liver metastases, should be enrolled in clinical trials where possible. 
Outcomes for loco-regional therapies such as microwave ablation (MA), radiofrequency 
ablation (RFA), irreversible electroporation or selective internal radiation therapy 
(SIRT) remain largely undetermined and prospective studies are required to evaluate 
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their benefit [11-14]. Results from a recently reported phase II study demonstrating 
improved overall survival in patients with up to 9 CLM treated with combined 
chemotherapy and RFA compared with chemotherapy alone suggests multi-modality 
treatment may be of benefit[15].Further UK guidelines addressing the resection of CLM 
were proposed by a select panel including liver surgeons, gastroenterologists, 
oncologists, diagnostic and interventional radiologists and general surgeons in 2006. It 
stated that patients under consideration of loco-regional treatment to hepatic 
metastases should be discussed within a specialist HPB MDM. In addition,consideration 
of patients for resection of liver metastases should be carried out by a high volume 
centre and the decision regarding fitness for surgery should be undertaken by an 
anaesthetist and liver surgeon. Despite these guidelines, there appears to be significant 
discordance within referral practices to specialist HPB MDMs and the subsequent 
management of liver-limited disease. The rate of CLM resection has been shown to vary 
significantly across the UK [16]. 
 
We conducted a study that retrospectively assessed referral rates for patients with 
liver-limited metastatic CRC to the central HPB MDM over a 6-month period, within a 
large dedicated cancer network. Cases that had not been discussed were then referred 
for virtual HPB MDM discussions with MDM contributors blinded to assess potential 
disparity between referral rates and suitability for surgery, SIRT or inclusion within a 
clinical trial. 
 
Methods 
A retrospective analysis was undertaken of all patients with liver-limited metastatic 
CRC across a 6-month period in 2012 within the South East London Cancer Network 
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(SELCN) and Kent and Medway Cancer Network (KMCN). The combined population 
served by these networks is approximately 2.9 million. All cases diagnosed with CRC 
within both networks during this time period were collated from local CRC MDM 
referral data.  From these records, all patients with liver limited CRC were then 
identified. Using information from a prospectively maintained MDM database from the 
HPB centre, patients were categorised into three groups; Patients referred to the 
specialist HPB MDM at diagnosis, those only referred following initial treatment and 
those that were never referred. Each referring hospital had a local CRC MDM that 
included colorectal surgeons, medical and clinical oncologists and diagnostic 
radiologists. In these hospitals, one of the specialist HPB surgeons from the tertiary liver 
centre attended these CRC MDMs monthly. The centre specialist HPB MDT occurred 
twice weekly and was attended by HPB surgeons, interventional radiologists, colorectal 
surgeons, histopathologists and medical and clinical oncologists. Information regarding 
baseline demographics, performance status [17], disease distribution and management 
were collated.  
For patients that had not been discussed within the specialist HPB MDM, a subsequent 
virtual MDM discussion with a liver surgeon, a dedicated liver radiologist and an 
oncologist was organised at the tertiary centre for all cases where imaging was 
available. Patients were discussed within ‘real-life’ MDMs and participating MDM 
contributors were blinded for each discussion. Proposed management was then 
compared with actual outcomes for each patient. 
To compare categorical variables, the chi-squared test or the Fischer’s exact test 
was used where appropriate. To compare continuous variables, the Mann-Whitney 
(two-tailed) test was used. Statistical analysis was performed using SPSS software 
package version 22.  
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Results                                                                                                               
159 patients with liver-limited metastatic colorectal cancer were identified. 68 patients 
(42.7%) were referred to the specialist HPB MDM at initial presentation of liver 
metastases, 38 patients (23.9%) were only referred following at least one course of 
systemic treatment and a further 53 patients (33.4%) were never referred to the HPB 
MDM. The median ages for patients referred at initial diagnosis, subsequent referrals 
and those not referred were 68.1, 65.1 and 69.9 respectively, without statistical 
difference between groups (p=0.23) (see Table 1.). 119 patients (79.3%) presented with 
synchronous liver metastases, 31 patients (20.6%) with metachronous disease and 
timing of hepatic spread was unknown for the remaining 9 patients (see Figure 1.). 
42.0% of patients with synchronous CLM were referred at initial diagnosis and 26.0% 
were only referred after systemic treatment. This was compared with 58.1% and 16.1% 
respectively for metachronous disease (P=0.11).  
Performance status [17] was available for 59 patients (37.0%) and was measured using 
the Eastern Cooperative Oncology Group Performance Status scale (ECOG PS). 52.5% of 
all patients referred at initial diagnosis had a PS of 0 or 1, and 6.0% had a PS of 2 or 
higher (PS was unknown for the remaining 41%) (Figure 2). For patients referred after 
initial treatment, 25% were 0-1 and 16% were 2 or higher.  22% of patients that were 
never referred had a good PS of 0 or 1, suggesting PS was not the reason for non- 
referral in this sub-group of patients where baseline fitness was known. Information 
regarding metastatic distribution was available for 140 (88%) patients. As expected, the 
majority of patients not referred to the MDM had multiple liver metastases. However 
24% with a solitary liver lesion were never referred to the HPB MDM (figure 3). 
Similarly, 26% with solitary sites of disease were only referred after systemic 
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treatment. Amongst the 68 patients that were referred at initial presentation, surgery or 
RFA was offered to 35 (51.5%) and SIRT was offered to 2 patients (2.9%) within the 
FOXFIRE trial (an open-label phase III trial of chemotherapy with or without 
radioembolisation for liver-limited metastatic CRC) [18]. Amongst the 38 patients that 
were referred following initial treatment to the MDM, resection or RFA was offered to 
18 patients (47.4%) and no patients were offered SIRT. Of patients that not discussed in 
the MDM, none had SIRT (Table 2). 81% of patients with liver metastases that were not 
referred to the specialist MDM were treated with systemic therapy including 
chemotherapy and antibody treatment.   
Of the 53 patients that were not referred to the specialist MDM, imaging was available 
for 31 patients and these patients were discussed in a virtual MDM. 25 of these patients 
had synchronous liver metastases and 6 had metachronous liver disease following 
initial management of the CRC primary tumour. Extra-hepatic disease was identified on 
imaging for 3 patients. For those with liver-limited cancer, imaging suggested 13 
patients (41.9%) had resectable or potentially resectable disease.  A further 11(35.5%) 
patients were potentially eligible for the FOXFIRE trial. The MDM recommendation for 5 
patients (16.1%) was palliative systemic therapy and for a further 2 (6.5%), proposed 
management was ‘best supportive care’ based on clinical information and imaging.  
 
Discussion 
This study demonstrated that a third of patients with liver-limited metastatic CRC 
within a large cancer network were never referred to a specialist HPB MDM. The role of 
metastasectomy in CRC has become standard practice and in a select group of patients 
can achieve outcomes similar to those seen with stage III disease. Yet determining 
which patients fall in to this category requires specialist consideration. With an evolving 
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definition of what constitutes resectable disease, the decision to operate or not must be 
made within an HPB MDM in order to ensure that operable cases are not missed.  
The reasons for non-referral are unknown and likely to be multi-factorial. One of the 
limitations to this study was that a complete medical history was not always available 
for each patient. It is possible that these patients may have had clear surgical contra-
indications or significant co-morbidities that may have rendered them unsuitable for 
resection. However the previously mentioned UK guidelines state that a liver surgeon 
and anaesthetist should determine surgical fitness. Dedicated HPB centres provide their 
own pre-assessment service designed to assess fitness depending on the procedure 
offered, as varying surgical and interventional techniques carry differing anaesthetic 
and surgical risk. Therefore to avoid discounting patients inappropriately, patients 
deemed unfit by referring hospitals still require specialist discussion. In addition 81% 
of all patients not referred, received systemic chemotherapy thereby confirming they 
had acceptable fitness for cytotoxic treatment.  
Imaging was not available for 22 of the 53 patients that were not referred to the MDM. 
Therefore our figures may be under representative of the cases suitable for surgery or 
loco-regional therapies. A previous study conducted in the north of England in 2009 
also found disparities in MDM referral rates[19].  Records of 631 patients with liver-
limited CRC within a cancer network were reviewed. 29% of patients not referred due 
to perceived inoperability despite good PS, were subsequently deemed operable 
following retrospective review of imaging by liver specialists. A further 15.3% had 
equivocal imaging. A subsequent separate study published in 2012 evaluated outcomes 
for a similar cohort of patients from a prospectively maintained database[20].. 110 
patients treated with palliative chemotherapy were identified over a 12-month period. 
53 patients that had not been discussed within a specialist HPB MDM had liver-limited 
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disease. Imaging for these patients were then reviewed by six liver surgeons who were 
blinded to patient details. 33 patients (63%) had tumours that were considered 
potentially resectable with a high level of inter-observer agreement. Despite these 
previous studies, our findings demonstrate that there remains a clear disparity between 
patients referred to the HPB MDM and those that should have been referred in 
accordance with current guidelines. Even if surgery is not possible for patients with 
liver limited disease, their tumours may be amenable to alternate loco-regional therapy 
offered by specialist HPB teams.  Although surgical techniques continue to improve and 
definitions of operability continue to be amended, not all patients with isolated liver 
disease are suitable for resection. For example, the number of liver metastases present 
has been found to be a predictor of poor survival [12, 21]. This emphasizes the 
importance of careful patient selection as even if disease can be resected, surgery may 
not impact outcome. Patients with limited liver metastases that are inoperable may 
benefit from loco-regional therapies but as there is limited prospective evidence for the 
survival benefits of such treatments, and as such these patients should be enrolled in 
clinical trials were available.  
The liver is the most common site for metastasectomy in CRC. However, there is also a 
role for directed therapy to other sites such as RFA or surgery to small volume lung 
metastases or even peritoneal disease. Therefore in the era of pioneering imaging, 
surgical and ablative techniques, a diagnosis of metastatic CRC is no longer synonymous 
with incurable disease. This important paradigm shift necessitates careful 
multidisciplinary planning of these select patients. The current universally accepted 
staging classification, the American Joint Committee on Cancer (AJCC) stage, does not 
reflect the intricacies of oligometastatic disease. A more sophisticated staging system 
may help identify patients suitable for curative therapy. Whilst the current 
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recommendations are to discuss all patients with liver-limited metastatic CRC in a 
specialist HPB MDM, it may be that these patients require their own MDM rather than 
be discussed amongst primary HPB cancer cases. For example a specialist ‘metastatic 
CRC MDM’ including colorectal, hepatobiliary and thoracic teams as well as 
interventional radiologists and oncologists could help select patients with low-volume 
metastatic disease suitable for metastastectomies or loco-regional therapy. 
Our study highlights the urgent need to improve referral practises to specialist HPB 
MDMs. Increased referrals are likely to equate to increased resection rates and 
subsequent improved survival for patients with liver-limited metastatic CRC. 
 
Future Directions 
In order to maintain uniformity of care in keeping with national guidance, all patients 
with oligometastatic CRC should be discussed within specialist MDM settings. For those 
with isolated CLM, images should be reviewed by hepatobiliary surgeons and 
radiologists to ensure surgery is offered where available. In cases where surgery is not 
possible, enrollment in clinical trials that include loco-regional therapies may be 
appropriate. For those with significant co-morbidities thought to be high risk, referral to 
tertiary liver centres should be made for assessment by a liver surgeon and anesthetist.  
 
 
 
 Total (N) Referred at 
first 
diagnosis 
Referred but 
not at first 
diagnosis 
Never referred 
Age 
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Average (years)         68.1 68.1 (31-
100) 
65.3 (34-81) 69.9 (40-90) 
31-40 4                        1 2 1 
41-50 4                       3 1 0 
51-60  29                      12 7 10 
61-70  37                      21 12 14 
71-80 48                      20 15 13 
81-90 32                     9 1 12 
91-100  2                    2 0 0 
Performance status 
0-1 40 21 (52.5%) 10 (25.0%) 9 (22.5%) 
2-4 19 6 (31.6%) 3 (15.7%) 10 (52.7%) 
Unknown 100 41 (41.0%) 25 (25.0%) 34 (34.0%) 
Presentation of metastatic disease 
Synchronous 119 50 (42.0%) 31 (26.0%) 38 (32.0%) 
Metachronous 31 18 (58.1%) 5 (16.1%) 8 (25.8%) 
Number of metastatic sites 
1 38 19 (50.0%) 10 (26.3%) 9 (23.7%) 
2-3 36 21 (58.3%) 12 (33.0%) 3 (8.7%) 
4-6 12 8 (61.5%) 3 (23.1%) 1(8%) 
Multiple 54 19 (35.2%) 12 (22.2%) 23(42.6%) 
 
 
Table 1. Patient demographics and disease distribution per referral group 
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Figure 1. Percentage of patients with synchronous and metachronous metastases per 
referral group. Patients were more likely to be referred at initial presentation if they 
had metachronous disease.  
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Figure 2. Eastern Cooperative Oncology Group Performance Status for patients at the 
time of diagnosis with liver metastases per referral group. More than 20% of patients 
with a good PS (0-1) were never referred to the HPB MDM. (PS=performance status, 
MDM=multi-disciplinary meeting).  
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Figure 3. Percentage of patients that presented with 1, 2-3, 4-6 or multiple liver 
metastases per referral group. More than 40%  of patients with a solitary liver 
metastasis were either not referred initially to the MDM or never referred.  
 
 
 
Table 2. Patients who underwent surgery, RFA or SIRT per referral group. None of the 
patients that were not referred to the MDM underwent liver directed therapy. There 
was no difference in surgical/RFA practices between patients who were referred at 
 Referred at first 
diagnosis 
Referred but not at 
first diagnosis 
Never referred 
Surgery/RFA 35/68 (51.5%) 18/38 (47.4%) 0/53 (0%) 
SIRT 2/68 (2.9%) 0/38 (0%) 0/53 (0%) 
1 2 OR 3 4 TO 6 MULTIPLE
0
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Number of liver metasatases
%
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initial diagnosis and those that were subsequently referred. (RFA = radiofrequency 
ablation, SIRT = selective internal radiation therapy, MDM = multi-disciplinary).  
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